Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges

Apogee Therapeutics, Inc. (APGE) has disclosed a new risk, in the Supply Chain category.

Apogee Therapeutics, Inc.’s reliance on foreign Contract Manufacturing Organizations (CMOs) such as WuXi Biologics and Samsung Biologics poses significant risks to its supply chain and clinical development timelines. The potential imposition of U.S. legislation like the BIOSECURE Act, along with existing and future tariffs on imports from China and South Korea, could escalate costs and disrupt material supply. Additionally, the unpredictable regulatory environment in China and evolving geopolitical tensions may further complicate Apogee’s operations, potentially delaying clinical trials and affecting financial stability. These factors collectively threaten to impact Apogee’s business prospects and its ability to secure government commitments for its therapies.

The average APGE stock price target is $96.75, implying 179.22% upside potential.

To learn more about Apogee Therapeutics, Inc.’s risk factors, click here.